The 1st Hawaii Global Summit on Breast Cancer is a five-day meeting comprising eight four-hour sessions with presentations by over 50  key opinion leaders. This summit assembles translational researchers, clinical researchers, and key community oncologists  to address and discuss challenges in the rapidly developing area of breast cancer and the evolution of treatment approaches.

Featuring didactic lectures, panel discussions, and case presentations highlighting individual patient challenges and new  approaches designed to overcome these challenges, the summit reviews compelling data on the effects of novel strategies.  There has been an explosion of new information from research on HER2+/HR-breast cancer, HR+/HER2-breast cancer, TNBC, antibody drug conjugates (ADCs), selective estrogen receptor degrader (SERDs), selective estrogen receptor modulator (SERMs), PARP inhibitors, checkpoint inhibitors. Presentations will be given by leading experts in the field of breast cancer who will offer further insight during question and-answer sessions. The challenges encountered in clinical management will be addressed in highly interactive sessions.  In addition to these leading experts, fellows and junior faculty will have the opportunity to present and discuss their  abstracts. Finally, industry representatives will showcase their data on emerging therapies that will be developed in the breast cancer space.

The Summit will review, cultivate, discuss and debate on the clinical and practical changes that will occur over the next five  years in the following areas of breast cancer:

• Immunotherapy and immune checkpoint inhibitors

• Approved and emerging tyrosine kinase inhibitors and other targeted agents

• Emerging antibody drug conjugates, antibodies, and CAR-T therapy